| Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study PM Doraiswamy, RA Sperling, RE Coleman, KA Johnson, EM Reiman, ... Neurology 79 (16), 1636-1644, 2012 | 261 | 2012 |
| Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study HH Fernandez, SA Factor, RA Hauser, J Jimenez-Shahed, WG Ondo, ... Neurology 88 (21), 2003-2010, 2017 | 201 | 2017 |
| Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial KE Anderson, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojärvi, ... The Lancet Psychiatry 4 (8), 595-604, 2017 | 188 | 2017 |
| Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals RA Sperling, KA Johnson, PM Doraiswamy, EM Reiman, AS Fleisher, ... Neurobiology of aging 34 (3), 822-831, 2013 | 146 | 2013 |
| Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo‐controlled trial D Weintraub, RA Hauser, JJ Elm, F Pagan, MD Davis, A Choudhry, ... Movement Disorders 31 (5), 709-714, 2016 | 76 | 2016 |
| Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia HH Fernandez, D Stamler, MD Davis, SA Factor, RA Hauser, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (12), 1317-1323, 2019 | 57 | 2019 |
| The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability NG LaRocca, LD Hudson, R Rudick, D Amtmann, L Balcer, R Benedict, ... Multiple Sclerosis Journal 24 (11), 1469-1484, 2018 | 56 | 2018 |
| Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis EM DeGoma, MD Davis, RL Dunbar, ER Mohler, P Greenland, B French Atherosclerosis 229 (2), 517-523, 2013 | 44 | 2013 |
| O Connell T, Johnson S, Cline S, Merikle E, Martenyi F, Simpson K. Estimating Alzheimer's disease progression rates from normal cognition through mild cognitive impairment and … M Davis Curr Alzheimer Res 15 (8), 777-788, 2018 | 40 | 2018 |
| Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate … O Khan, P Rieckmann, A Boyko, K Selmaj, N Ashtamker, MD Davis, ... Multiple Sclerosis Journal 23 (6), 818-829, 2017 | 39 | 2017 |
| A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis CJ Ross, F Towfic, J Shankar, D Laifenfeld, M Thoma, M Davis, B Weiner, ... Genome medicine 9, 1-15, 2017 | 34 | 2017 |
| Restoring ecological flows to the lower Savannah River: a collaborative scientific approach to adaptive management A Wrona, D Wear, J Ward, R Sharitz, J Rosenzweig, JP Richardson, ... Proceedings of the 2007 Georgia Water Resources Conference, 27-29, 2007 | 22 | 2007 |
| Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set MW Koch, GR Cutter, G Giovannoni, BMJ Uitdehaag, JS Wolinsky, ... Neurology: Neuroimmunology & Neuroinflammation 4 (4), e358, 2017 | 20 | 2017 |
| Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study MD Davis, N Ashtamker, JR Steinerman, V Knappertz Neurology: Neuroimmunology & Neuroinflammation 4 (2), e327, 2017 | 17 | 2017 |
| 149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study KE Anderson, MD Davis, SA Factor, RA Hauser, LF Jarskog, ... CNS Spectrums 23 (1), 92-93, 2018 | 7 | 2018 |
| The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis R Zivadinov, MG Dwyer, DP Ramasamy, MD Davis, JR Steinerman, ... Journal of Neuroimaging 25 (6), 989-995, 2015 | 6 | 2015 |
| Academic Seismic Portal (ASP) at UTIG G Christeson, T Shipley, L Gahagan, K Johnson, M Davis Austin, TX: University of Texas Institute for Geophysics. http://wwwudc. ig …, 2017 | 5 | 2017 |
| Seismic Data Center, University of Texas Institute for Geophysics T Shipley, L Gahagan, K Johnson, M Davis URL http://www. ig. utexas. edu/sdc/(Last accessed October 23, 2013), 2005 | 5 | 2005 |
| Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate … P Rieckmann, R Zivadinov, A Boyko, K Selmaj, JK Alexander, S Kadosh, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 7 (4 …, 2021 | 4 | 2021 |
| Addressing involuntary movements in tardive dyskinesia (AIM-TD): effect of fixed-dose deutetrabenazine by baseline comorbidities (S56. 006) KE Anderson, SA Factor, MD Davis, RA Hauser, J Isojarvi, ... Neurology 88 (16_supplement), S56. 006, 2017 | 4 | 2017 |
